FREMONT, Calif.--(BUSINESS WIRE)--Moximed, an innovative medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced the closing on $61 million of Series D preferred stock financing with an option to close on up to an additional $30 million.

加利福尼亚州弗里蒙特市（商业新闻短讯）--创新医疗器械公司Moximed今天宣布，D系列优先股融资6100万美元，并有权再融资3000万美元。

The round was led by Elevage Medical Technologies, a Patient Square Capital platform, with participation from new investors Cormorant Asset Management and Warren Point Capital and existing investors New Enterprise Associates (NEA), Future Fund, Advent Life Sciences, Gilde Healthcare, Vertex Ventures HC, GBS Venture Partners, and Morgenthaler Ventures..

这一轮由患者广场资本平台Elevate Medical Technologies牵头，新投资者Cormorant Asset Management和Warren Point Capital以及现有投资者new Enterprise Associates（NEA）、Future Fund、Advent Life Sciences、Gilde Healthcare、Vertex Ventures HC、GBS Venture Partners和Morgenthaler Ventures参与。。

Proceeds from the financing will be used to accelerate U.S. commercialization of Moximed’s MISHA® Knee System, the world’s first implantable shock absorber (ISA) for knee osteoarthritis. OA is a common, debilitating condition, affecting the lives of over 32 million adults in the U.S, and projected to impact 70 million Americans by 2040..

融资收益将用于加速美国Moximed MISHA®膝关节系统的商业化，该系统是世界上第一个用于膝关节骨性关节炎的植入式减震器（ISA）。OA是一种常见的衰弱性疾病，影响着美国3200多万成年人的生活，预计到2040年将影响7000万美国人。。

Moximed utilized the clinically established benefits of weight load reduction on diseased joints to design and develop the MISHA Knee System, which is dedicated to helping people with mild-to-moderate OA preserve their knee joints while enjoying active lives. Implanted during an outpatient procedure, the MISHA Knee System has been shown to alleviate pain, improve function, and delay the need for total knee replacement in some patients..

Moximed利用临床上确定的减轻患病关节体重的益处来设计和开发MISHA膝关节系统，该系统致力于帮助轻度至中度OA患者在享受积极生活的同时保护膝关节。MISHA膝关节系统在门诊手术期间植入，已被证明可以缓解疼痛，改善功能，并延迟一些患者进行全膝关节置换的需要。。

“This financing is validation of the significant market opportunity for the MISHA Knee System,” said Chris Gleason, President and Chief Executive Officer of Moximed. “We are seeing tremendous interest from surgeons and patients, and we are excited to rapidly expand our commercial infrastructure to address evolving patient needs in this growing market.”.

Moximed总裁兼首席执行官克里斯·格里森（ChrisGleason）表示：“此次融资验证了MISHA膝关节系统的重大市场机遇。”。“我们看到外科医生和患者产生了巨大的兴趣，我们很高兴能够迅速扩展我们的商业基础设施，以满足这个不断增长的市场中不断变化的患者需求。”。

As part of the financing, Michael Wasserman, Ph.D., of Elevage Medical will join Moximed’s Board of Directors. Prior to Elevage, Dr. Wasserman served as Managing Partner of Maverix Private Equity and spent 17 years at H.I.G. Capital. Dr. Wasserman has served on the boards of numerous growth-stage businesses including HyperBranch Medical Technologies (Stryker), NeuWave Medical (Johnson & Johnson), and VertiFlex (Boston Scientific).

作为融资的一部分，Elevage Medical的Michael Wasserman博士将加入Moximed的董事会。在加入Elevage之前，Wasserman博士曾担任Maverix Private Equity的管理合伙人，并在H.I.G.Capital工作了17年。Wasserman博士曾在许多成长期企业的董事会任职，包括超支医疗技术（Stryker）、NeuWave医疗（Johnson＆Johnson）和VertiFlex（Boston Scientific）。

“Elevage is thrilled to partner with Moximed as it continues to generate commercial momentum,” stated Wasserman. “The size of Moximed’s market opportunity, the product differentiation, and its clinical value proposition are highly compelling attributes. We are pleased that our investment will help fuel significant expansion of the Moximed business and positively impact the lives of countless patients.”.

沃瑟曼表示：“Elevage很高兴与Moximed合作，因为它继续产生商业势头。”。“Moximed的市场机会规模、产品差异化及其临床价值主张都是极具吸引力的因素。我们很高兴我们的投资将有助于推动Moximed业务的大幅扩张，并对无数患者的生活产生积极影响。”。

“A medical device financing of this magnitude is a strong vote of confidence in this competitive funding environment,” said James Leech, Chief Financial and Strategy Officer of Moximed. “Our unique market opportunity, technology, and high caliber team enabled us to attract blue-chip investors in this important financing.

Moximed首席财务和战略官詹姆斯·利奇（JamesLeech）表示：“如此规模的医疗器械融资是对这种竞争性融资环境的有力信心投票。”。“我们独特的市场机会、技术和高素质的团队使我们能够在这一重要融资中吸引蓝筹股投资者。

We look forward to using these proceeds to expand patient and surgeon access to our breakthrough technology.”.

我们期待着利用这些收益扩大患者和外科医生对我们突破性技术的访问。”。

“I am extremely proud of the Moximed team for taking the next steps in delivering a highly impactful product that addresses a significant clinical need for a large number of people,” noted Josh Makower, M.D., Co-founder and Chairman of the Board of Directors of Moximed. “The MISHA Knee System has the potential to help millions of patients suffering from medial knee OA who are not ready for joint replacement.”.

Moximed联合创始人兼董事会主席Josh Makower医学博士表示：“我为Moximed团队采取下一步行动，提供了一种极具影响力的产品，满足了大量人群的重大临床需求而感到无比骄傲。”。“MISHA膝关节系统有可能帮助数百万膝关节内侧OA患者，这些患者尚未做好关节置换的准备。”。

About Moximed

关于Moximed

Moximed’s technology, the MISHA Knee System, is the result of over a decade of clinical research and development and is the first implantable shock absorber for the treatment of medial compartment knee osteoarthritis (OA). With experienced med-tech leadership and strong investor support, Moximed is poised to elevate the standard of care and quality of life for millions of pre-arthroplasty knee OA sufferers hindered by arthritic knee pain and function loss.

Moximed的MISHA膝关节系统技术是十多年临床研究和开发的结果，是第一个用于治疗膝关节内侧骨关节炎（OA）的植入式减震器。凭借经验丰富的医学技术领导和强大的投资者支持，Moximed有望提高数百万膝关节置换术前膝关节OA患者的护理水平和生活质量，这些患者受到膝关节炎疼痛和功能丧失的阻碍。

Moximed is based in Fremont, California..

Moximed总部位于加利福尼亚州弗里蒙特。。

To learn more, visit www.moximed.com.

To learn more, visit www.moximed.com.

About The MISHA® Knee System

关于MISHA®膝关节系统

Moximed’s MISHA Knee System is for people with medial knee OA who failed to find relief from previous treatments. These patients continue to experience pain that interferes with daily activities, and are ineligible for, or unwilling to undergo, joint replacement due to age or absence of advanced OA..

Moximed的MISHA膝关节系统适用于膝关节内侧OA患者，这些患者未能从以前的治疗中缓解。这些患者继续经历干扰日常活动的疼痛，并且由于年龄或缺乏晚期OA而不符合或不愿意接受关节置换术。。

Knee OA develops when the joint’s natural shock absorbers, cartilage and meniscus, no longer cushion the joint from daily activities, leading to chronic pain and activity limitation. Many people with mild to moderate OA are otherwise healthy, in their prime working years, and have busy lives. For these patients, total knee replacement is a reluctant option, as it is an end-stage treatment for end-stage disease.

当关节的自然减震器，软骨和半月板不再缓冲关节日常活动时，膝关节OA就会发展，导致慢性疼痛和活动受限。许多患有轻度至中度OA的人在其工作的黄金时期都很健康，并且生活繁忙。对于这些患者来说，全膝关节置换术是一种不情愿的选择，因为它是终末期疾病的终末期治疗方法。

OA patients without end-stage disease seek options that preserve their knee, activity level, and quality of life..

没有终末期疾病的OA患者寻求保护膝盖，活动水平和生活质量的选择。。

Reducing weight on painful osteoarthritic joints is known to reduce pain and improve function. The MISHA Knee System is the first implantable shock absorber that reduces weight on the knee joint with every walking step, easing pain, preserving function, and possibly delaying joint replacement surgery.

已知减轻疼痛的骨关节炎关节的体重可以减轻疼痛并改善功能。MISHA膝关节系统是第一个植入式减震器，它可以在每一步行走时减轻膝关节的重量，减轻疼痛，保持功能，并可能延迟关节置换手术。

The implant is placed on the medial knee and moves with the natural joint, reducing about 30% of the peak force on the knee with every walking step..

植入物放置在膝盖内侧，并与自然关节一起移动，每走一步，膝盖上的峰值力就会减少约30%。。

The MISHA Knee System is FDA cleared.

MISHA膝盖系统已获得FDA批准。

About Elevage Medical Technologies

关于Elevage Medical Technologies

Elevage Medical Technologies is a platform established by Patient Square Capital and is dedicated to supporting medical technology companies that can meaningfully improve health outcomes and quality of life for patients. Elevage provides capital along with deep technical, regulatory, and operational expertise to companies ranging from advanced clinical development to commercial acceleration stage.

Elevate Medical Technologies是由Patient Square Capital建立的一个平台，致力于支持能够有意义地改善患者健康状况和生活质量的医疗技术公司。Elevage为从高级临床开发到商业加速阶段的公司提供资金以及深入的技术、监管和运营专业知识。

Elevage supports rapidly growing, highly differentiated companies with paradigm shifting technologies and strives to help build industry leading medical technology businesses. To learn more about Elevage, please visit www.elevagemedical.com..

Elevage支持快速增长、高度分化的公司，采用范式转换技术，并努力帮助建立行业领先的医疗技术业务。要了解更多有关Elevage的信息，请访问www.elevagemedical.com。。